Chapter

Aromatase inhibitors in early and advanced disease

Laura Boehnke Michaud

in Endocrine Therapies in Breast Cancer

Published on behalf of Oxford University Press

ISBN: 9780199218141
Published online May 2011 | e-ISBN: 9780199606993 | DOI: http://dx.doi.org/10.1093/med/9780199218141.003.0004

Series: Oxford Oncology Library

Aromatase inhibitors in early and advanced disease

Show Summary Details

Preview

• Aromatase inhibitors are effective endocrine therapies for postmenopausal women with metastatic breast cancer. • Compared with tamoxifen, the new generation aromatase inhibitors are generally better tolerated with less associated morbidity. • For early stage breast cancer, new generation aromatase inhibitors should be incorporated into adjuvant therapy for hormonally sensitive, postmenopausal breast cancer. • The optimal method to incorporate the aromatase inhibitors into the adjuvant treatment of early stage breast cancer is unknown. • The use of these agents in premenopausal women is contraindicated unless in the context of a clinical trial in combination with ovarian ablation or suppression.

Chapter.  5383 words.  Illustrated.

Subjects: Clinical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.